Budesonid potvrdil efekt v léčbě IgA nefropatie ve studii NefIgArd: konec éry systémových kortikosteroidů?

Abstrakt

Souhrn s komentářem. Citace: Barratt J, Lafayette R, Kristensen J, et al.; for the NefIgArd Trial Investigators.

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int 2023;103:391-40.